[8-K] Editas Medicine, Inc. Reports Material Event

Rhea-AI Filing Summary

Editas Medicine announced that it has furnished a press release reporting its financial results for the fiscal quarter ended June 30, 2025 and other business highlights. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is expressly furnished, not filed, so the numerical results and business detail are contained in that exhibit rather than in the body of the filing.

Insights

Financial Analyst

TL;DR: Routine earnings press release furnished; the filing contains no financial figures here to evaluate impact.

The Form 8-K indicates Editas furnished a press release with results for the quarter ended June 30, 2025, but no revenue, expense, profit or cash metrics are included in this filing text. Because the substantive financial information is provided in Exhibit 99.1 rather than in the filing narrative, this 8-K does not by itself allow assessment of earnings trends, margin changes, or cash position. Investors and analysts should review Exhibit 99.1 directly for material figures and context.

Corporate Governance Expert

TL;DR: Procedural disclosure furnished to satisfy reporting obligations; legal exposure is limited by the "furnished, not filed" status.

The company explicitly states the press release (Exhibit 99.1) is being furnished and not deemed "filed" under the Exchange Act, which limits Section 18 liability and prevents automatic incorporation by reference into other filings. The report is signed on behalf of the company by Amy Parison, Chief Financial Officer, indicating appropriate officer certification of the submission. This is a routine regulatory disclosure rather than a governance change or corporate action.

0001650664FALSE00016506642025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________________________________

FORM 8-K

_________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

_________________________________________________________________________________________

Editas Medicine, Inc.

(Exact Name of Registrant as Specified in its Charter)

_________________________________________________________________________________________

Delaware			001-37687			46-4097528
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

11 Hurley Street
Cambridge,			Massachusetts			02141
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s telephone number, including area code: (617) 401-9000

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.0001 par value per share			EDIT			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press release issued by the Company on August 12, 2025*
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

*This exhibit shall be deemed to be furnished and not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EDITAS MEDICINE, INC.
Date: August 12, 2025			By:			/s/ Amy Parison
						Amy Parison
						Chief Financial Officer

FAQ

What did Editas (EDIT) announce in this 8-K?

Editas furnished a press release announcing financial results for the fiscal quarter ended June 30, 2025 and other business highlights; the release is Exhibit 99.1.

Where can I find the detailed financial results for Editas' quarter ended June 30, 2025?

The detailed results are provided in Exhibit 99.1 to this Current Report on Form 8-K (the press release attached to the filing).

Is the press release in this 8-K considered filed or furnished?

The press release is expressly furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated by reference into other filings unless specifically stated.

Which period do the results cover in the Editas announcement?

The results cover the fiscal quarter ended June 30, 2025.

Who signed the Form 8-K for Editas?

The report is signed on behalf of Editas by Amy Parison, Chief Financial Officer.